Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled) A liposome-based parenteral composition comprising:
   (a) an effective amount of an active ingredient comprising erythropoietin or its pharmaceutically acceptable derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells;
   (b) a lipidic phase comprising:
      (i) lecithin or hydrogenated lecithin;
      (ii) optionally, a charged electropositive or electronegative lipid compound and
      (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterols; and
   (c) a phosphate buffer.

2. (Amended) The composition of claim ~~1~~ 14, wherein the composition comprises single bilayered liposomes made by preparing a solution of the lipidic phase in an alcoholic solvent and injecting the solution under pressure into the aqueous buffer solution contained in a high speed homogenizer.

3. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, ~~characterized in that it comprises furthermore~~ further comprising a stabilizer.

4. (Amended) The ~~liposome-based formulation~~ composition of claim 3, wherein the stabilizer is glycine.

5. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, wherein the lecithin is hydrogenated lecithin.

6. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, wherein the charged electropositive or electronegative lipid compound is selected from dipalmitoyl phosphatidic acid (DPPA), di-palmitoylglycerole (DPPG), oleyl amine and stearyl amine.

7. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, wherein the buffer is selected from sodium dihydrogen phosphate dihydrate, di-sodium hydrogen phosphate dihydrate, and mixtues thereof.

8. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, characterized in that it furthermore comprises a preserving agent.

9. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, characterized in that it furthermore comprises an antioxidant.

10. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, characterized in that it furthermore comprises a complexing agent.

11. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, characterized in that it has the following composition:

	g/100g
EPO or analogous compounds	200,000 U - 1 Mill. Units
Lecithin hydrogenated (Soya)	0.5 - 5.000
Cholesterol	0.1 - 1.000
Charged lipid	0.05 - 0.5
Ethanol	0.5 - 5.000
Glycine	0.0 - 1.00
Buffer	0 to 2.0
Water	q.s ad 100.0.

12. (Amended) ~~The liposome-based formulation of claim 1 for use as a~~ A pharmaceutical preparation for the treatment of anemia comprising the liposomal-based composition of claim 14 .

13. (Amended) The ~~liposome-based formulation~~ composition of claim ~~1~~ 14, characterized in that it has the following composition:

	g/100 g
Erythropoietin	1 Million I.U.
Lecithin (Soya) hydrogenated	0.500
Cholesterol	0.100
DPPA-Na	0.040
Ethanol Pharma Undenatured	0.500
Sodium Dihydrogenphosphate Dihydrate	0.1164
di-Sodium Hydrogen Phosphate Dihydrate	0.2225
Sodium Chloride	0.584
Water purified	97.9371

14. (New) A liposomal-based parenteral composition comprising:

(a) an aqueous phase comprising an aqueous buffer solution;

(b) a lipidic phase comprising liposomes dispersed within the aqueous phase; and

(c) an effective amount of an active ingredient comprising erythropoietin or its pharmaceutically acceptable derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, said active ingredient being dispersed within the aqueous phase and being substantially unincorporated within the liposomes.